SAN RAFAEL, Calif. & BARCELONA--(BUSINESS WIRE)--Dec 7, 2022--
IMIDomics, Inc., a biotechnology company focused on the discovery and development of new medicines for the treatment of patients with immune-mediated inflammatory diseases (IMIDs), announced today the formation of an Immunology Advisory Board consisting of a number of scientific and industry luminaries with experience in developing and bringing to market new therapies targeting IMIDs.
“As we continue to refine our Precision Discovery Engine, move forward with identifying and pursuing targets for potential new treatments and forge key partnership within the pharmaceutical and biotechnology space, having this seasoned, respected and passionate group of advisors will be key to ensuring we’re maximizing the potential of IMIDomics to deliver meaningful results for IMID patients,” said Fred Craves, CEO of IMIDomics. “We are honored and excited to work closely with each of them and tap their unparalleled expertise.”
Members of the IMIDomics Immunology Advisory Board include:
ABOUT IMIDOMICS, INC.
IMIDomics, Inc. is a privately held global biotechnology company focused on the discovery and development of new medicines for the treatment of immune-mediated inflammatory diseases (IMIDs). Utilizing an exclusive commercial license with the Vall d’Hebron Hospital IMID Biobank’s to access anonymized data from more than 17,000 patients across 150 health centers, IMIDomics specializes in generating unique insights into IMID patient experiences, conditions and underlying disease mechanisms. This data forms the foundation of the IMIDomics Precision Discovery™ Engine which leverages state-of-the-art analytics, machine learning and bioinformatics expertise to uncover new insights about IMIDs based on precisely defined patient populations. These insights are enabling new discoveries for treatments, diagnostics and other innovations designed to address the unmet needs of people living with these complex and challenging diseases.
IMIDomics was founded in Barcelona, Spain in 2015 by Dr. Sara Marsal, Head of the Rheumatology Department at the Vall d’Hebron University Hospital, and Dr. Richard M. Myers, President and Scientific Director at the HudsonAlpha Institute for Biotechnology. Existing investors in IMIDomics include DNS Capital, Tao Capital, The Pritzker Organization, Evotec and Bristol Myers Squibb. To learn more about IMIDomics, please visit www.imidomics.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20221207005088/en/
CONTACT: IMIDomics Press Contact:
Casey Blickenstaff at Real Chemistry
cblickenstaff@realchemistry.com
KEYWORD: EUROPE SPAIN UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES GENERAL HEALTH RESEARCH SCIENCE PHARMACEUTICAL BIOTECHNOLOGY
SOURCE: IMIDomics, Inc.
Copyright Business Wire 2022.
PUB: 12/07/2022 11:00 AM/DISC: 12/07/2022 11:03 AM
http://www.businesswire.com/news/home/20221207005088/en